Apogee Therapeutics Q1 2026 Net Loss $74.11M Vs. Loss Of $55.34M YoY, Cash, Cash Equivalents, Marketable Securities And Long-term Marketable Securities Were $1.3B As Of March 31, 2026, With Cash Runway Into 2029